Incyte

Incyte Announces Final Results of Tender Offer

Retrieved on: 
木曜日, 6月 13, 2024
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Corporation, Computershare, Goldman Sachs, Incyte, Baker, Cryptocurrency

Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the final results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024.

Key Points: 
  • Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the final results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024.
  • Incyte has accepted for purchase 27,866,666 shares of its common stock at a purchase price of $60.00 per share, for a total cost of approximately $1.672 billion, excluding fees and expenses relating to the tender offer.
  • The final proration factor for the shares that Incyte will purchase pursuant to the tender offer is approximately 93.5 percent.
  • Stockholders who have questions or would like additional information about the tender offer may contact D.F.

Incyte Announces Preliminary Results of Tender Offer

Retrieved on: 
火曜日, 6月 11, 2024
Professional Services, Health, Finance, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Corporation, Computershare, Goldman Sachs, Incyte, Hand, Baker, Cryptocurrency

Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the preliminary results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024.

Key Points: 
  • Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the preliminary results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024.
  • Incyte has been informed by the depositary that the preliminary proration factor for the shares to be purchased by Incyte pursuant to the tender offer is approximately 93.4 percent.
  • In accordance with the terms and conditions of the tender offer and based on the preliminary count by the depositary, the Company expects to purchase approximately 27.9 million shares of its common stock through the tender offer at a purchase price of $60.00 per share, for a total cost of approximately $1.672 billion, excluding fees and expenses relating to the tender offer.
  • The number of shares expected to be purchased in the tender offer and under the stock purchase agreement and the purchase price per share are preliminary and subject to change.

Dr. Michael Donovan Joins Cellworks to Oversee Personalized Cancer Therapy Biosimulation in New CLIA-Certified Lab

Retrieved on: 
火曜日, 5月 28, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Software, Science, Clinical Trials, Patient, TRI, Doctor of Philosophy, Boston Children's Hospital, Medicare, Incyte, Machine learning, Takeda Oncology, CBM, Rutgers University, Developmental Biology (journal), University, Lung cancer, New Jersey Medical School, Neoplasm, CLIA, Publication, NSCLC, CGP, Harvard Medical School, Fellow, Hospital, Genomics, Laboratory, Pharmaceutical industry

Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.

Key Points: 
  • Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.
  • This new facility signifies a major step forward in Cellworks’ aim to establish a novel transformation in Personalized Therapy Decision Support with an initial focus on delivering personalized therapy predictions for non-small cell lung cancer (NSCLC) patients.
  • The Cellworks Platform coupled with its in silico Computational Biology Model (CBM) utilizes genomic aberrations from a patient’s cancer tumor to reveal how the tumor will respond to therapies.
  • “We have an incredible opportunity to pioneer advancements in Personalized Therapy Biosimulation, starting with important breakthroughs for NSCLC patients.

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Retrieved on: 
金曜日, 4月 26, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, School, University, Global Oncology, Cancer, Wastewater treatment, University of Pennsylvania, Pharmacovigilance, Incyte, Hematology, GSK plc, Drug, Partnership, MPM, Senior, Patient, Therapy, Head

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024.
  • “On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare into the leading precision oncology company that it is today.
  • "I look forward to the ongoing advancement of Repare’s pipeline and its continued progress as a leading precision oncology company."
  • Dr. Stein also previously served on the board of directors of Kura Oncology, Inc. from 2017 until May 2023.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
水曜日, 1月 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
火曜日, 11月 14, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Sale, Webcast, ID, Completeness, Incyte, Patient, Research, Chief commercial officer, APL, Bone marrow, RARA, Acute promyelocytic leukemia, Retirement, AML, Growth, Arsenic trioxide, Syro, Pharmaceutical industry, Management, Cryptocurrency, Pfizer, Syros

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.
  • In October 2023, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., effective December 1, 2023.
  • General and administrative expenses were $7.8 million for the third quarter of 2023, as compared to $8.1 million for the third quarter of 2022.
  • ET to discuss these third quarter 2023 financial results and provide a corporate update.

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

Retrieved on: 
水曜日, 11月 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Genzyme, Therapy, Commerce, University, Acquisition, Doctor of Philosophy, MBA, BIO, Incyte, Wharton School of the University of Pennsylvania, Growth, BioMarin Pharmaceutical, Retirement, Widener University Commonwealth Law School, JJ, Genentech, Cancer, Pharmacy, Patient, Jean-Jacques, Pharmaceutical Research and Manufacturers of America, Management, Genencor, Immunome

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors.
  • Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.
  • “Immunome is pleased to welcome JJ to the Board of Directors as we enter our next stage of growth,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • His guidance will be essential as we advance our pipeline of potential first-in-class and best-in-class targeted cancer therapies.”
    “I am excited to join the Immunome Board of Directors as they work to bring transformative oncology therapeutics to the patients most in need,” commented Mr. Bienaimé.

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Retrieved on: 
木曜日, 11月 2, 2023
Neoplasm, Research, NSCLC, Biomarker, Pembrolizumab, Betta, Castration, HIV disease progression rates, Cetuximab, Partnership, NRG1, Cancer, Drug design, PSA, ESMO, Head, Prostate cancer, Abstract (summary), Pancreatic cancer, ORR, Douglas BTD Destroyer, Safety, PDAC, Patient, EAP, Eli Lilly and Company, Congress, ADT, Clinical trial, CT, Oncology, European Society for Medical Oncology, Toxic leukoencephalopathy, FDA, Lilly, CD3, Aes, HER2, Afatinib, RECIST, Lung cancer, MET, BLA, FTD, Mutation, EGFR, Pharmaceutical industry, Life insurance, Vaccine, Medical imaging, Telescope, Bank, Tutoring, Birth control, CRPC, HNSCC, Incyte, Meru Networks

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.

Key Points: 
  • In the planned trial, patients will be randomized to petosemtamab monotherapy or investigators’ choice of single agent chemotherapy or cetuximab.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Initial safety data from this single arm cohort may support the initiation of a first-line registration trial with this combination.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

Retrieved on: 
金曜日, 10月 27, 2023
Biotechnology, Health, Professional Services, Pharmaceutical, Human Resources, Environment, Culture, Workplace, Social responsibility, Patient, Human resources, Management, Newsweek, Incyte, Science

Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals.

Key Points: 
  • Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals.
  • Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized for its loyal employees, social responsibility and treating employees with respect.
  • Incyte is proud to be recognized as a top employer by Science and seeks to create an environment where innovation, collaboration and respect for each other are prioritized.
  • The complete Science magazine Top Employers survey feature, along with individual company rankings, is available in the October 27, 2023 print issue of Science and online: https://www.science.org/content/article/making-happy-workplace-employees .

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Retrieved on: 
木曜日, 11月 2, 2023
Data, GVHD, Society, ASH, SNDX, Safety, Patient, BLA, Pharmaceutical industry, Incyte

WALTHAM, Mass., Nov. 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that results from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (cGVHD), will be featured during the Plenary Scientific Session at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California.

Key Points: 
  • "Inclusion of AGAVE-201 in this year's ASH plenary session further supports our belief that axatilimab has the potential to serve as a highly differentiated therapeutic option for patients with chronic GVHD," said Michael A. Metzger, Chief Executive Officer.
  • "We believe axatilimab's best-in-category profile and unique mechanism of action positions it as an important addition to the chronic GVHD treatment armamentarium, if approved.
  • Furthermore, axatilimab was generally well tolerated, and the most common adverse events were consistent with on-target effects and prior trials.
  • In addition, preclinical data detailing the anti-inflammatory and anti-fibrotic mechanism through which axatilimab is thought to impact the disease process in cGVHD will be featured during a poster session.